Marizyme, Inc.
MRZM · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $0 | $0 |
| % Growth | 176.6% | 11% | 6.7% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 37% | 76.7% | 61.8% | 70.4% |
| R&D Expenses | $2 | $4 | $2 | $1 |
| G&A Expenses | $15 | $8 | $7 | $5 |
| SG&A Expenses | $17 | $8 | $7 | $5 |
| Sales & Mktg Exp. | $2 | $0 | $0 | $0 |
| Other Operating Expenses | $15 | $1 | $0 | $1 |
| Operating Expenses | $34 | $13 | $9 | $6 |
| Operating Income | -$34 | -$13 | -$9 | -$6 |
| % Margin | -5,278.1% | -5,556.6% | -4,195.1% | -2,941.9% |
| Other Income/Exp. Net | -$31 | -$1 | -$2 | -$0 |
| Pre-Tax Income | -$65 | -$38 | -$11 | -$6 |
| Tax Expense | $4 | $0 | $0 | $0 |
| Net Income | -$70 | -$38 | -$11 | -$6 |
| % Margin | -10,767.8% | -16,346.2% | -5,230.2% | -2,965% |
| EPS | -1.53 | -0.94 | -0.31 | -0.22 |
| % Growth | -62.8% | -203.2% | -40.9% | – |
| EPS Diluted | -1.53 | -0.94 | -0.31 | -0.22 |
| Weighted Avg Shares Out | 45 | 41 | 36 | 26 |
| Weighted Avg Shares Out Dil | 45 | 41 | 36 | 26 |
| Supplemental Information | – | – | – | – |
| Interest Income | $10 | $0 | $0 | $0 |
| Interest Expense | $30 | $3 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $0 | $1 |
| EBITDA | -$55 | -$35 | -$11 | -$5 |
| % Margin | -8,585.2% | -14,791.2% | -5,149.4% | -2,641.9% |